<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37119480</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Protein kinetics of superoxide dismutase-1 in familial and sporadic amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1012</StartPage><EndPage>1024</EndPage><MedlinePgn>1012-1024</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51784</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Accumulation of misfolded superoxide dismutase-1 (SOD1) is a pathological hallmark of SOD1-related amyotrophic lateral sclerosis (ALS) and is observed in sporadic ALS where its role in pathogenesis is controversial. Understanding in vivo protein kinetics may clarify how SOD1 influences neurodegeneration and inform optimal dosing for therapies that lower SOD1 transcripts.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We employed stable isotope labeling paired with mass spectrometry to evaluate in vivo protein kinetics and concentration of soluble SOD1 in cerebrospinal fluid (CSF) of SOD1 mutation carriers, sporadic ALS participants and controls. A deaminated SOD1 peptide, SDGPVKV, that correlates with protein stability was also measured.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In participants with heterozygous SOD1<sup>A5V</sup> mutations, known to cause rapidly progressive ALS, mutant SOD1 protein exhibited ~twofold faster turnover and&#x2009;~&#x2009;16-fold lower concentration compared to wild-type SOD1 protein. SDGPVKV levels were increased in SOD1<sup>A5V</sup> carriers relative to controls. Thus, SOD1 mutations impact protein kinetics and stability. We applied this approach to sporadic ALS participants and found that SOD1 turnover, concentration, and SDGPVKV levels are not significantly different compared to controls.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">These results highlight the ability of stable isotope labeling approaches and peptide deamidation to discern the influence of disease mutations on protein kinetics and stability and support implementation of this method to optimize clinical trial design of gene and molecular therapies for neurological disorders.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinicaltrials.gov: NCT03449212.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ly</LastName><ForeName>Cindy V</ForeName><Initials>CV</Initials><Identifier Source="ORCID">0000-0002-7063-5170</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ireland</LastName><ForeName>Margaret D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Self</LastName><ForeName>Wade K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollinger</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jockel-Balsarotti</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herzog</LastName><ForeName>Hillary</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allred</LastName><ForeName>Peggy</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Leah</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doyle</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anez-Bruzual</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trikamji</LastName><ForeName>Bhavesh</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Ted</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8652-8129</Identifier><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bucelli</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Bruce W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Department of Medicine, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-3424-5511</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03449212</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 DK056341</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS107621</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS107621</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097816</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097816</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>CVL has received research funding from Target ALS and consulting fees from Biogen. KN has received research funding from AI Therapeutics and Alector Therapeutics, and consulting fees from Biogen, MT Pharma of America, Regeneron, and Amylyx Therapeutics while employed by Massachusetts General Hospital. KN is now employed by Sanofi. RCB receives consulting fees from Biogen and receives research funding from Biogen and Ionis Pharmaceuticals for clinical trials. RCB serves on an advisory board for Biogen and has equity in Neuroquestions. RJB has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb, and Novartis. Washington University and RJB have equity ownership interest in C2N Diagnostics and receive income based on technology (stable isotope labeling kinetics, blood plasma assay, and methods of diagnosing AD with phosphorylation changes) licensed by Washington University to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board. TMM has licensing agreements with C2N Diagnostics and Ionis Pharmaceuticals and receives consulting fees from Biogen, Biolo, LLC, Cytokinetics, Disarm, Ionis Pharmaceuticals, and UCB.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>29</Day><Hour>19</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>29</Day><Hour>14</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37119480</ArticleId><ArticleId IdType="pmc">PMC10270254</ArticleId><ArticleId IdType="doi">10.1002/acn3.51784</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wright GSA, Antonyuk SV, Hasnain SS. The biophysics of superoxide dismutase&#x2010;1 and amyotrophic lateral sclerosis. Q Rev Biophys. 2019;52:e12. (In Eng). doi:10.1017/s003358351900012x</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s003358351900012x</ArticleId><ArticleId IdType="pubmed">31760962</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali T, Self W, Liu J, et&#xa0;al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry. 2017;88(2):99&#x2010;105. (In Eng). doi:10.1136/jnnp-2016-313521</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313521</ArticleId><ArticleId IdType="pmc">PMC5136332</ArticleId><ArticleId IdType="pubmed">27261500</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, Asayama K, Hirano A, Kobayashi M. Immunohistochemical study on superoxide dismutases in spinal cords from autopsied patients with amyotrophic lateral sclerosis. Dev Neurosci. 1996;18(5&#x2013;6):492&#x2010;498. (In Eng). doi:10.1159/000111445</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000111445</ArticleId><ArticleId IdType="pubmed">8940623</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Lee MK, Slunt HS, et&#xa0;al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci U S A. 1994;91(17):8292&#x2010;8296. (In Eng). doi:10.1073/pnas.91.17.8292</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.17.8292</ArticleId><ArticleId IdType="pmc">PMC44592</ArticleId><ArticleId IdType="pubmed">8058797</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrawell NE, Yerbury JJ. Mutant Cu/Zn superoxide dismutase (A4V) turnover is altered in cells containing inclusions. Front Mol Neurosci. 2021;14:771911. (In Eng). doi:10.3389/fnmol.2021.771911</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.771911</ArticleId><ArticleId IdType="pmc">PMC8597841</ArticleId><ArticleId IdType="pubmed">34803609</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisp MJ, Mawuenyega KG, Patterson BW, et&#xa0;al. In vivo kinetic approach reveals slow SOD1 turnover in the CNS. J Clin Invest. 2015;125(7):2772&#x2010;2780. doi:10.1172/JCI80705</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI80705</ArticleId><ArticleId IdType="pmc">PMC4563686</ArticleId><ArticleId IdType="pubmed">26075819</ArticleId></ArticleIdList></Reference><Reference><Citation>Farr GW, Ying Z, Fenton WA, Horwich AL. Hydrogen&#x2010;deuterium exchange in vivo to measure turnover of an ALS&#x2010;associated mutant SOD1 protein in spinal cord of mice. Protein Sci. 2011;20(10):1692&#x2010;1696. doi:10.1002/pro.700</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.700</ArticleId><ArticleId IdType="pmc">PMC3218362</ArticleId><ArticleId IdType="pubmed">21780215</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Nakanishi T, Yamamoto Y, et&#xa0;al. Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology. 2005;65(12):1954&#x2010;1957. doi:10.1212/01.wnl.0000188760.53922.05</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000188760.53922.05</ArticleId><ArticleId IdType="pubmed">16291929</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotunno MS, Bosco DA. An emerging role for misfolded wild&#x2010;type SOD1 in sporadic ALS pathogenesis. Front Cell Neurosci. 2013;7:253. doi:10.3389/fncel.2013.00253</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00253</ArticleId><ArticleId IdType="pmc">PMC3863749</ArticleId><ArticleId IdType="pubmed">24379756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Morfini G, Karabacak NM, et&#xa0;al. Wild&#x2010;type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010;13(11):1396&#x2010;1403. doi:10.1038/nn.2660</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2660</ArticleId><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg K, Andersen PM, Marklund SL, Brannstrom T. Glial nuclear aggregates of superoxide dismutase&#x2010;1 are regularly present in patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2011;121(5):623&#x2010;634. doi:10.1007/s00401-011-0805-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0805-3</ArticleId><ArticleId IdType="pmc">PMC3085063</ArticleId><ArticleId IdType="pubmed">21287393</ArticleId></ArticleIdList></Reference><Reference><Citation>Brotherton TE, Li Y, Cooper D, et&#xa0;al. Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS. Proc Natl Acad Sci U S A. 2012;109(14):5505&#x2010;5510. doi:10.1073/pnas.1115009109</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1115009109</ArticleId><ArticleId IdType="pmc">PMC3325721</ArticleId><ArticleId IdType="pubmed">22431618</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HN, Sanelli T, Horne P, et&#xa0;al. Lack of evidence of monomer/misfolded superoxide dismutase&#x2010;1 in sporadic amyotrophic lateral sclerosis. Ann Neurol. 2009;66(1):75&#x2010;80. doi:10.1002/ana.21704</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21704</ArticleId><ArticleId IdType="pubmed">19670443</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S, Bui A, Saberi S, et&#xa0;al. Misfolded SOD1 is not a primary component of sporadic ALS. Acta Neuropathol. 2017;134(1):97&#x2010;111. doi:10.1007/s00401-017-1688-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1688-8</ArticleId><ArticleId IdType="pmc">PMC5472502</ArticleId><ArticleId IdType="pubmed">28247063</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist BG, Genoud S, Roudeau S, et&#xa0;al. Altered SOD1 maturation and post&#x2010;translational modification in amyotrophic lateral sclerosis spinal cord. Brain. 2022;145(9):3108&#x2010;3130. doi:10.1093/brain/awac165</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac165</ArticleId><ArticleId IdType="pmc">PMC9473357</ArticleId><ArticleId IdType="pubmed">35512359</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Genge A, et&#xa0;al. Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099&#x2010;1110. doi:10.1056/NEJMoa2204705</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et&#xa0;al. Phase 1&#x2010;2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2010;119. doi:10.1056/NEJMoa2003715</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Berry JD, McKenna&#x2010;Yasek DM, et&#xa0;al. SOD1 suppression with adeno&#x2010;associated virus and MicroRNA in familial ALS. N Engl J Med. 2020;383(2):151&#x2010;158. doi:10.1056/NEJMoa2005056</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Self WK, Schoch KM, Alex J, et&#xa0;al. Protein production is an early biomarker for RNA&#x2010;targeted therapies. Ann Clin&#xa0;Transl Neurol. 2018;5(12):1492&#x2010;1504. doi:10.1002/acn3.657</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.657</ArticleId><ArticleId IdType="pmc">PMC6292185</ArticleId><ArticleId IdType="pubmed">30564616</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson RW, Gabelle A, Lucey BP, et&#xa0;al. SILK studies &#x2013; capturing the turnover of proteins linked to neurodegenerative diseases. Nat Rev Neurol. 2019;15(7):419&#x2010;427. doi:10.1038/s41582-019-0222-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0222-0</ArticleId><ArticleId IdType="pmc">PMC6876864</ArticleId><ArticleId IdType="pubmed">31222062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Klunk WE. Measuring target effect of proposed disease&#x2010;modifying therapies in Alzheimer's disease. Neurotherapeutics. 2008;5(3):381&#x2010;390. doi:10.1016/j.nurt.2008.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nurt.2008.05.009</ArticleId><ArticleId IdType="pmc">PMC2588423</ArticleId><ArticleId IdType="pubmed">18625449</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Siemers ER, Mawuenyega KG, et&#xa0;al. A gamma&#x2010;secretase inhibitor decreases amyloid&#x2010;beta production in the central nervous system. Ann Neurol. 2009;66(1):48&#x2010;54. doi:10.1002/ana.21623</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21623</ArticleId><ArticleId IdType="pmc">PMC2730994</ArticleId><ArticleId IdType="pubmed">19360898</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, et&#xa0;al. Decreased clearance of CNS beta&#x2010;amyloid in Alzheimer's disease. Science. 2010;330(6012):1774. doi:10.1126/science.1197623</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1197623</ArticleId><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Barthelemy NR, Mawuenyega KG, et&#xa0;al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;98(4):861&#x2010;864. doi:10.1016/j.neuron.2018.04.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.04.035</ArticleId><ArticleId IdType="pmc">PMC6192252</ArticleId><ArticleId IdType="pubmed">29772204</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker&#x2010;Nigh AT, Mawuenyega KG, Bollinger JG, et&#xa0;al. Human central nervous system (CNS) ApoE isoforms are increased by age, differentially altered by amyloidosis, and relative amounts reversed in the CNS compared with plasma. J Biol Chem. 2016;291(53):27204&#x2010;27218. doi:10.1074/jbc.M116.721779</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.721779</ArticleId><ArticleId IdType="pmc">PMC5207148</ArticleId><ArticleId IdType="pubmed">27793990</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosal K, Haag M, Verghese PB, et&#xa0;al. A randomized controlled study to evaluate the effect of bexarotene on amyloid&#x2010;beta and apolipoprotein E metabolism in healthy subjects. Alzheimers Dement (N Y). 2016;2(2):110&#x2010;120. doi:10.1016/j.trci.2016.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2016.06.001</ArticleId><ArticleId IdType="pmc">PMC5644280</ArticleId><ArticleId IdType="pubmed">29067298</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertsman I, Wuu J, McAlonis&#x2010;Downes M, et&#xa0;al. An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis. JCI Insight. 2019;4(10):e122768. doi:10.1172/jci.insight.122768</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.122768</ArticleId><ArticleId IdType="pmc">PMC6542602</ArticleId><ArticleId IdType="pubmed">31092730</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Becher MW, Lee MK, et&#xa0;al. ALS&#x2010;linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1&#x2010;containing inclusions. Neuron. 1997;18(2):327&#x2010;338. doi:10.1016/s0896-6273(00)80272-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0896-6273(00)80272-x</ArticleId><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist BG, Hilton JB, Hare DJ, Crouch PJ, Double KL. Superoxide dismutase 1 in health and disease: how a frontline antioxidant becomes neurotoxic. Angew Chem Int ed Engl. 2021;60(17):9215&#x2010;9246. doi:10.1002/anie.202000451</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202000451</ArticleId><ArticleId IdType="pmc">PMC8247289</ArticleId><ArticleId IdType="pubmed">32144830</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt AJ, Shin DS, Merz GE, et&#xa0;al. Aggregation propensities of superoxide dismutase G93 hotspot mutants mirror ALS clinical phenotypes. Proc Natl Acad Sci U S A. 2014;111(43):E4568&#x2010;E4576. doi:10.1073/pnas.1308531111</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1308531111</ArticleId><ArticleId IdType="pmc">PMC4217430</ArticleId><ArticleId IdType="pubmed">25316790</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Hart PJ, Borchelt DR, Andersen PM. Variation in aggregation propensities among ALS&#x2010;associated variants of SOD1: correlation to human disease. Hum Mol Genet. 2009;18(17):3217&#x2010;3226. doi:10.1093/hmg/ddp260</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp260</ArticleId><ArticleId IdType="pmc">PMC2722984</ArticleId><ArticleId IdType="pubmed">19483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Acerson MJ, Abdolvahabi A, Mowery RA, Shaw BF. Gibbs energy of superoxide dismutase heterodimerization accounts for variable survival in amyotrophic lateral sclerosis. J Am Chem Soc. 2016;138(16):5351&#x2010;5362. doi:10.1021/jacs.6b01742</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.6b01742</ArticleId><ArticleId IdType="pubmed">27054659</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer L, Srinivasan D, Chun S, et&#xa0;al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70(2):201&#x2010;207. doi:10.1001/jamaneurol.2013.593</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.593</ArticleId><ArticleId IdType="pmc">PMC3812918</ArticleId><ArticleId IdType="pubmed">23147550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterstrom P, Andersen PM, Brannstrom T, Marklund SL. Misfolded superoxide dismutase&#x2010;1 in CSF from amyotrophic lateral sclerosis patients. J Neurochem. 2011;117(1):91&#x2010;99. doi:10.1111/j.1471-4159.2011.07177.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07177.x</ArticleId><ArticleId IdType="pubmed">21226712</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiber H. Flow rate of cerebrospinal fluid (CSF)&#x2013;a concept common to normal blood&#x2010;CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci. 1994;122(2):189&#x2010;203. doi:10.1016/0022-510x(94)90298-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510x(94)90298-4</ArticleId><ArticleId IdType="pubmed">8021703</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>